---
schema_version: "secwatch.filing_event.v1"
accession: "0001759425-25-000003"
form_type: "8-K"
ticker: "MIRM"
cik: "0001759425"
company_name: "Mirum Pharmaceuticals, Inc."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:40:59.716143+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Mirum Pharma 2024 net sales ~$336M, above guidance; 2025 outlook $420-435M

## Summary
- Preliminary unaudited FY2024 net product sales ~$336M, exceeding upper end of guidance range.
- LIVMARLI net sales ~$213M; CHOLBAM/CHENODAL ~$123M; Q4 2024 sales ~$99M.
- 2025 guidance: global net product sales $420-435M with positive cash flow from operations.
- Year-end cash and investments ~$287M; achieved positive cash from operations in Q3 2024.
- Pipeline: PDUFA date for chenodiol in CTX March 28, 2025; volixibat VISTAS enrollment completion H2 2025.

## SEC filing metadata
- accession: 0001759425-25-000003
- form_type: 8-K
- ticker: MIRM
- cik: 0001759425
- company_name: Mirum Pharmaceuticals, Inc.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759425/000175942525000003/0001759425-25-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759425/000175942525000003/mirm-20250113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001759425-25-000003
- JSON: https://secwatch.observer/filing/0001759425-25-000003.json
- Plain text: https://secwatch.observer/filing/0001759425-25-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.